The effects of synbiotic product on gut microbiota changes in patients with multiple sclerosis treated with dimethyl fumarate
Phase 3
Recruiting
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20190804044429N12
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Adults over 18 years of age with a recent diagnosis of MS or a first attack consistent with a high-risk primary clinical syndrome based on the McDonald 2017 criteria
Expanded disability status scale less than 4.5
Candidate for dimethyl fumarate
Exclusion Criteria
Pregnancy
Antibiotic use in the past month
Consumption of any product and supplement that contains probiotics during the last three months
Consumption of omega-3 and other antioxidants during the last month
Systemic glucocorticoid use during the last month
breastfeeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in the bacteria in the digestive tract of people with MS. Timepoint: At the beginning of treatment and month 6. Method of measurement: PCR.
- Secondary Outcome Measures
Name Time Method